Last Updated: November 18, 2026

Details for Patent: 5,616,346

« Back to Dashboard


Summary for Patent: 5,616,346
Title:Non-aqueous colonic purgative formulations
Abstract:Orally administered colonic purgative formulations and methods of its use for effecting partial or complete purgation of the colon in mammals, the formulations consisting of non-aqueous admixtures of monobasic, dibasic and tribasic sodium phosphates administered in tablet or capsule form in concentrations of from 0.01 to 0.85 grams per kilogram body weight. Preferred embodiments include the addition of binders, dispersants and buffers which do not adversely affect osmolality or effectiveness of the purgative formulations.
Inventor(s):Craig A. Aronchick
Assignee: ARONCHICK LIPSCHUTZ AND WRIGHT PARTNERSHIP , CDC III LLC
Application Number:US08/669,834
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;
Patent landscape, scope, and claims:

United States Patent 5,616,346: Scope, Claims, Expiration, and Sodium Phosphate Purgative Patent Landscape

U.S. Patent No. 5,616,346 protected dry, orally administered sodium phosphate bowel-cleansing compositions in tablet or gelatin-capsule form and methods of using those dosage forms without first dissolving them in water. The patent issued April 1, 1997, and its enforceable term has expired. The patent therefore no longer blocks generic manufacture, sale, or use in the United States, although later patents, FDA requirements, product liability issues, and sodium-phosphate safety restrictions may still affect commercial entry.

The claims are directed principally to the solid dosage-form concept associated with sodium phosphate bowel preparations such as Visicol and OsmoPrep, rather than to a new sodium phosphate molecule.

What does U.S. Patent 5,616,346 protect?

The patent has four substantive claim groups:

Claim group Protected subject matter Principal limitations
Claims 1-8 Composition claims Sodium phosphate salt, nonaqueous tablet or gelatin capsule, optional additives
Claims 9-16 General method claims Preparing, forming, and administering a dry sodium phosphate dosage form
Claims 17-18 Narrow method claims Approximately 72% monobasic and 26% dibasic sodium phosphate in tablets
Claim 19 Narrow composition claim Approximately 70%-73% monobasic, 26%-30% dibasic, and 1%-4% inert additives

The patent does not broadly cover every sodium phosphate laxative. The strongest protection is directed to a dry dosage form that contains sodium phosphate salts and is administered orally without prior dispersion in water.

The central commercial concept is a tablet or capsule that disperses after reaching the stomach and produces colonic purgation while reducing the volume of liquid the patient must drink compared with conventional aqueous bowel-preparation solutions.

How should the independent claims be construed?

Claim 1: solid sodium phosphate composition

Claim 1 requires a composition that:

  1. Is orally administrable.
  2. Is capable of dispersing in the stomach.
  3. Induces colonic purgation in humans.
  4. Contains an effective purgative amount of at least one sodium phosphate salt.
  5. Is nonaqueous.
  6. Is a tablet or gelatin capsule.
  7. May contain buffering, dispersal, or binding agents.

The phrase "consisting essentially of" is important. It permits ingredients that do not materially alter the basic purgative operation of the composition but excludes additional active or functional components that materially change the invention.

A liquid sodium phosphate preparation would fall outside the express tablet-or-capsule limitation of claim 1. A tablet containing a non-sodium-phosphate osmotic laxative as an additional active ingredient would face a substantial "consisting essentially of" issue.

Claim 9: preparation and administration method

Claim 9 requires a sequence of steps:

  • Preparing a nonaqueous sodium phosphate mixture.
  • Forming a dry oral dosage form.
  • Administering the dosage form without dispersing it in water beforehand.
  • Allowing it to induce purgation.

This claim is narrower than a claim to sodium phosphate administration generally. It focuses on the dosage-form process and the absence of pre-administration dissolution.

A product administered as a pre-mixed liquid would not satisfy the express dry-dosage-form limitations. A product supplied as a powder but routinely dissolved before administration would also create a noninfringement argument under the claim language.

Claim 17: dosage and composition combination

Claim 17 requires:

  • Approximately 72% monobasic sodium phosphate.
  • Approximately 26% dibasic sodium phosphate.
  • Orally administrable tablets.
  • Dibasic sodium phosphate administered at 0.1-0.5 grams per kilogram of body weight.

This claim combines composition, dosage form, and dosing limitations. It is narrower than claim 1 and more vulnerable to noninfringement based on salt ratio, tablet composition, or administered dose.

Claim 19: commercial-product profile

Claim 19 is the most product-specific composition claim. It requires:

  • 70%-73% monobasic sodium phosphate.
  • 26%-30% dibasic sodium phosphate.
  • 1%-4% inert additives.
  • Tablets or gelatin capsules.
  • A composition capable of dispersing in the stomach and inducing colonic purgation.

The percentages appear to describe the active salt blend used in commercial sodium phosphate tablets. Because the ranges collectively can total between 96% and 107%, the claim does not require a mathematically fixed 100% composition in every possible reading. In practice, however, a commercial formulation would normally be evaluated on a normalized weight basis.

Which claim limitations create the main infringement risks?

Limitation Scope effect Design-around opportunity
"Nonaqueous form" Excludes conventional liquid preparations Use an aqueous preparation
"Tablets and gelatin capsules" Excludes many powders, granules, and liquids Use a different dosage form
"At least one sodium phosphate salt" Captures monobasic, dibasic, and tribasic salts Use a non-phosphate osmotic agent
"Consisting essentially of" Limits additional ingredients that materially alter operation Add a different active or functional excipient, subject to construction
Stomach dispersal Requires post-administration dispersion capability Develop an enteric, delayed-release, or non-dispersing dosage form
Human or mammalian purgation Limits the claimed therapeutic purpose Avoid the claimed use, where commercially practical
70%-73% monobasic and 26%-30% dibasic Creates a numerical range for the narrow claims Shift salt ratios outside the claimed ranges
0.1-0.5 g/kg dibasic dose Narrows claims 14 and 17 Use a different dosage or dosing schedule

The broadest practical risk under the issued claims concerns a tablet or gelatin capsule containing sodium phosphate as the operative purgative, administered without prior dissolution. Claims 2-4 and 17-19 create additional risk when the formulation approximates the monobasic/dibasic ratios used in commercial products.

What formulations are protected by the patent?

The patent claims the following formulation classes:

Monobasic sodium phosphate formulations

Claim 2 identifies monobasic sodium phosphate at approximately 70%-73% by weight. This is a relatively narrow composition limitation and does not cover every monobasic sodium phosphate tablet.

Dibasic sodium phosphate formulations

Claim 3 identifies dibasic sodium phosphate at approximately 26%-30% by weight. The claim does not require monobasic sodium phosphate unless that limitation is imported through another claim.

Mixed monobasic and dibasic formulations

Claim 4 covers a mixture having approximately 70%-73% monobasic sodium phosphate and 26%-30% dibasic sodium phosphate. Claim 19 adds a 1%-4% range for inert additives and is more closely aligned with a finished commercial tablet.

Tribasic-containing formulations

Claims 5, 15, and 16 include formulations containing tribasic sodium phosphate. Claims 6-8 address selected additives, including magnesium hydroxide, aluminum hydroxide, calcium carbonate, magnesium carbonate, lactose, microcrystalline cellulose, AC-DI-SOL, nonionic detergents, and mechanical adhesives.

The additive claims are dependent claims. They do not independently protect the listed excipients in other drug products. They apply only when the base sodium phosphate composition and the other limitations of the referenced claim are present.

When did U.S. Patent 5,616,346 lose exclusivity?

The patent issued on April 1, 1997. Its 17-year patent term expired on April 1, 2014, subject to any patent-term adjustment or other term event recorded by the USPTO. Public patent records identify the patent as expired. The patent cannot currently provide enforceable United States exclusivity over the claimed sodium phosphate tablets or methods. (U.S. Patent No. 5,616,346, 1997; USPTO, n.d.)

Because the patent is expired:

  • A new Paragraph IV challenge is commercially unnecessary.
  • A generic applicant does not need to wait for this patent to expire.
  • The patent cannot support a current injunction against an accused product.
  • Historical infringement claims remain subject to applicable limitation periods and procedural defenses.
  • Any continuing exclusivity must arise from a different patent, regulatory exclusivity, or commercial protection.

What is the Orange Book status of the patent?

Patent 5,616,346 should be treated as an expired historical patent rather than a live Orange Book barrier. FDA Orange Book listing is product-specific and does not itself extend the patent term. A patent may be listed during a drug product's commercial life, but an expired listed patent does not create a current legal barrier to approval after expiration. (U.S. Food and Drug Administration, n.d.-a)

The relevant FDA products include prescription sodium phosphate tablet bowel preparations such as Visicol and OsmoPrep. FDA labeling identifies sodium phosphate tablet products as requiring substantial liquid intake and includes warnings concerning renal injury, electrolyte abnormalities, and high-risk patient populations. (U.S. Food and Drug Administration, n.d.-b; U.S. Food and Drug Administration, n.d.-c)

FDA approval does not establish freedom to operate. A later patent covering a formulation, coating, manufacturing process, dosing regimen, or approved use could remain relevant even after the 5,616,346 patent expired.

What Paragraph IV challenges and litigation affected the patent?

Paragraph IV litigation is relevant only while an Orange Book-listed patent is unexpired or otherwise legally enforceable. The expiration of 5,616,346 eliminates the patent as a current Paragraph IV obstacle.

The commercial litigation risk for sodium phosphate tablets historically would have focused on:

  • Whether a generic tablet contained the claimed monobasic/dibasic ratio.
  • Whether the product was capable of dispersing in the stomach.
  • Whether the composition contained only permitted ingredients under "consisting essentially of."
  • Whether the proposed label induced the claimed purgation method.
  • Whether the product met the claimed dose ranges.

A later generic product could still face litigation over separate patents. Patent 5,616,346 alone does not support a current infringement action.

How does the patent compare with later sodium phosphate product protection?

The patent has moderate historical strength but limited current commercial strength.

Factor Assessment
Chemical composition Weak current protection because sodium phosphate salts are established materials
Dosage form Historically meaningful protection for tablets and capsules
Salt-ratio ranges Narrow and potentially useful against close copies
Method of use Narrow because it requires dry dosage-form preparation and administration
Formulation additives Limited to dependent-claim combinations
Manufacturing process Little protection in the supplied claims
Current enforceability None after expiration
Regulatory relevance Product-specific; FDA approval remains separate from patent rights
Generic entry risk High as to this patent
Biosimilar risk Not applicable

The patent does not protect a biologic and has no biosimilar pathway relevance. Sodium phosphate tablets are small-molecule drug products. Any follow-on competitor would generally evaluate an abbreviated new drug application, labeling requirements, bioequivalence, product quality, and clinical safety rather than a biosimilar application.

What manufacturing and intellectual-property barriers remain?

The expired patent does not eliminate operational barriers. A commercial entrant would still need to address:

  • Consistent tablet weight and hardness.
  • Rapid gastrointestinal dispersion.
  • Sodium and phosphate load control.
  • Stability of the active salts and excipients.
  • Packaging that limits moisture exposure.
  • Dose accuracy across a multi-tablet regimen.
  • Renal and cardiovascular safety warnings.
  • Patient instructions concerning liquid intake.
  • FDA manufacturing and quality-system requirements.

The supplied claims contain no express protection for a specific compression process, coating process, packaging system, tablet tooling configuration, or impurity-control method. Those areas could be covered by later patents or trade secrets, but they are not protected by the quoted claims of Patent 5,616,346.

What licensing deals and commercial relationships are relevant?

The principal commercial history is associated with prescription sodium phosphate tablet products, including Visicol and OsmoPrep. Product commercialization, corporate acquisition, distribution, or marketing arrangements should not be treated as continuing patent licenses after the patent's expiration.

No license is necessary to practice the expired claims. A party acquiring rights to a commercial brand, regulatory dossier, trademark, manufacturing technology, or later patent family could still require contractual rights, but those rights would be separate from Patent 5,616,346.

What generic launch scenarios exist?

Immediate tablet-based entry

A manufacturer could develop a sodium phosphate tablet with a different salt ratio, alternative excipient system, or different dosing profile. Because Patent 5,616,346 is expired, the patent itself would not delay launch.

Close formulation copy

A product matching the 70%-73% monobasic and 26%-30% dibasic ranges would have faced historical claim risk during the patent term. Today, the principal obstacles would be FDA approval, safety, quality, and any later unexpired patents.

Alternative dosage form

A powder, liquid, effervescent product, or delayed-release dosage form could avoid the express tablet-or-gelatin-capsule limitations. The alternative would still require separate regulatory and technical validation.

Lower-volume or modified regimen

A lower-dose formulation could avoid the narrow method claims tied to specified gram-per-kilogram ranges. It would not automatically avoid broader composition claims during the historical patent term, but that issue is no longer operative because the patent has expired.

What is the geographic scope of the patent?

Patent 5,616,346 had United States territorial scope only. It did not directly control products sold in Canada, Europe, Japan, or other markets. Foreign equivalents, continuations, divisionals, and later improvement patents would require separate review.

The expiration analysis above applies to the United States patent. It should not be extended automatically to foreign patent families or to later patents claiming the same commercial products.

Key Takeaways

  • U.S. Patent 5,616,346 covers dry sodium phosphate purgative tablets and gelatin capsules and methods of administering them without prior dissolution.
  • The broadest practical claim concept is a nonaqueous sodium phosphate tablet or capsule that disperses in the stomach and induces colonic purgation.
  • Claims 17 and 19 are narrower and focus on approximately 72% monobasic and 26% dibasic sodium phosphate, with specified dosing or inert-additive ranges.
  • The patent issued April 1, 1997, and its 17-year term expired April 1, 2014, subject to any recorded term adjustment.
  • The patent is no longer a current Orange Book or Paragraph IV barrier.
  • Biosimilar analysis is not relevant because sodium phosphate products are small-molecule drug products.
  • Current competitive risk must be assessed against later patents, FDA requirements, safety restrictions, manufacturing know-how, and trademarks rather than Patent 5,616,346.

FAQs

Does Patent 5,616,346 cover liquid sodium phosphate bowel preparations?

No. The quoted composition claims require a nonaqueous dosage form selected from tablets and gelatin capsules. A liquid product would not satisfy those express limitations.

Does the patent cover any tablet containing sodium phosphate?

No. The claims require a combination of limitations, including a purgative amount, a nonaqueous oral dosage form, and the claimed stomach-dispersal and purgation characteristics. The narrow claims also require specified salt ratios or dosing ranges.

Can a generic manufacturer copy the monobasic and dibasic sodium phosphate ratios today?

Patent 5,616,346 no longer prevents that conduct because the patent has expired. The manufacturer must still address other unexpired patents, FDA approval, labeling, quality, and safety requirements.

Are the excipient claims independently enforceable?

No. Claims 6-8 are dependent claims. They apply only when the underlying sodium phosphate composition and the limitations of the referenced claims are also satisfied.

Does expiration of Patent 5,616,346 mean that Visicol or OsmoPrep can be marketed without FDA approval?

No. Patent expiration removes one intellectual-property barrier. It does not eliminate the requirement for FDA approval, compliance with approved labeling, current good manufacturing practices, or applicable drug-safety controls.

References

U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

U.S. Food and Drug Administration. (n.d.-b). OsmoPrep prescribing information. https://www.accessdata.fda.gov

U.S. Food and Drug Administration. (n.d.-c). Visicol prescribing information. https://www.accessdata.fda.gov

U.S. Food and Drug Administration. (2014). FDA drug safety communication: FDA recommends separating dosing of sodium phosphate products used for bowel cleansing. https://www.fda.gov

U.S. Patent No. 5,616,346. (1997). Orally administrable sodium phosphate purgative compositions and methods. United States Patent and Trademark Office.

United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 5,616,346

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 5,616,346

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 235894 ⤷  Start Trial
Canada 2241445 ⤷  Start Trial
Germany 69627170 ⤷  Start Trial
Denmark 0858326 ⤷  Start Trial
European Patent Office 0858326 ⤷  Start Trial
Spain 2196149 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.